ClinicaliQ Trial Snapshot
- Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency — Recruiting • Phase III • NCT06948214.
- New oral medication tested in children with growth hormone deficiency to see if it works and identify who benefits most.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The OraGrowtH Phase 3 Trial is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate the LUM-201 predictive enrichment marker (LUM-201 PEM) strategy to select subjects likely to respond to therapy with daily oral LUM-201. Conditions: Growth Hormone Deficiency (GHD) Interventions: LUM-201, Matched Placebo (Capsules) Lead Sponsor: Lumos Pharma Planned Enrollment: 150 participants